cAMP analogue 8-CPT-cAMP inducing differentiation in the M2b subtype of acute myeloid leukemia cell line Kasumi-1.
- Author:
Qi ZHU
1
;
Jun-Pei HU
;
Pei-Min JIA
;
Zhen-Yi WANG
;
Jian-Hua TONG
Author Information
1. Department of Hematology, Shanghai Ninth People Hospital, Shanghai Jiaotong University Medical College, Shanghai 200011, China. zhuqi70@hotmail.com
- Publication Type:Journal Article
- MeSH:
Cell Transformation, Neoplastic;
drug effects;
Core Binding Factor Alpha 2 Subunit;
genetics;
metabolism;
Cyclic AMP;
analogs & derivatives;
pharmacology;
Humans;
Leukemia, Myeloid, Acute;
genetics;
metabolism;
pathology;
Oncogene Proteins, Fusion;
genetics;
metabolism;
RUNX1 Translocation Partner 1 Protein;
Thionucleotides;
pharmacology;
Tumor Cells, Cultured
- From:
Journal of Experimental Hematology
2008;16(1):44-47
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the possible effects of cyclic adenosine monophosphate (cAMP) analogue 8-(4-chlorophenylthio) adenosine 3', 5'-cyclic monophosphate (8-CPT-cAMP) on the M(2b) subtype of acute myeloid leukemia (AML-M(2b)) cells. AML-M(2b) is characterized by the non-random chromosome translocation t (8; 21) (q22; q22), through which AML1 (acute myeloid leukemia 1) gene on chromosome 21 is fused with ETO (eight twenty-one) gene on chromosome 8, coding correspondent AML1-ETO fusion protein, which plays a crucial role in the leukemogenesis of AML-M(2b). The AML-M(2b) cell line Kasumi-1 cells were used as an in vitro model. The influences of 8-CPT-cAMP on the proliferation and differentiation of Kasumi-1 cells were evaluated according to cellular morphology, changes in cell surface antigen and cell cycle, as well as nitroblue-tetrazolium (NBT) assay. Meanwhile, semi-quantity RT-PCR and Western blot assay were used to detect the degradation of AML1-ETO fusion protein in Kasumi-1 cells before and after the treatment. The results showed that 8-CPT-cAMP (200 micromol/L) could significantly inhibit cell growth and induce differentiation of Kasumi-1 cells. However, it must be pointed out that 8-CPT-cAMP-induced differentiation in Kasumi-1 is not a typical terminal differentiation. Furthermore, 8-CPT-cAMP exerted little influence on the expression of AML1-ETO fusion gene and its product in Kasumi-1 cells. In conclusion, the 8-CPT-cAMP induced differentiation in Kasumi-1 cells. This results may provide experimental and theoretical basis for the breakthrough of differentiation-induced therapy extended to another leukemia.
